Loading...
•
Dec 31, 2025
FMC Q4 2025 Earnings Report
FMC Corporation reported a decline in revenue and net income for the fourth quarter of 2025, primarily due to a non-cash goodwill impairment and lower pricing.
Key Takeaways
FMC Corporation experienced a challenging fourth quarter in 2025, with revenue declining by 12% to $1.08 billion and a significant GAAP net loss of $1.72 billion, largely driven by a non-cash goodwill impairment. Despite these headwinds, the company is focusing on strategic priorities for 2026, including strengthening its balance sheet and exploring strategic options to unlock shareholder value.
Fourth quarter 2025 revenue declined by 12% to $1.08 billion compared to the prior year.
The company reported a GAAP net loss of $1.72 billion for Q4 2025, primarily due to a non-cash goodwill impairment.
Adjusted EBITDA for Q4 2025 was $280 million, a 17% decrease from the prior-year period.
FMC Corporation announced an exploration of strategic options, including a potential sale of the company, to enhance shareholder value and position its portfolios for long-term success.
Revenue by Geographic Location
Forward Guidance
FMC Corporation anticipates a decline in full-year 2026 revenue and Adjusted EBITDA, primarily due to lower pricing and the exclusion of India sales. However, growth in new active ingredients is expected to partially offset these declines.
Positive Outlook
- Sales of new active ingredients are expected to grow over 75% at the midpoint, reaching between $300 million and $400 million.
- Excluding India, volume is expected to be up modestly due to increases in branded Rynaxypyr® and new active ingredients.
- Manufacturing costs are expected to be favorable, providing a tailwind for full-year 2026.
- EBITDA margins in subsequent quarters of 2026 are expected to return to more historical levels from higher sales and favorable costs.
- The exploration of strategic options aims to unlock shareholder value and ensure long-term success for valuable assets and pipeline.
Challenges Ahead
- Full-year 2026 revenue guidance is $3.60 billion to $3.80 billion, a decline of 5% at the midpoint versus prior year.
- Price is expected to be lower by mid-single digits, mainly due to Rynaxypyr® post-patent strategy.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...